Celldex laces up next to Big Pharma players as drug reduces severity of chronic hives

Celldex Therapeutics has some huge competition in immunology, but new phase 2 data from its monoclonal antibody showing a reduction in the severity of a chronic form of hives is helping put the biotech in the game.